Filing Flows › Hyster-Yale (HY) › Takeover & LBO
Is Hyster-Yale (HY) a takeover target?
A leveraged buyout does not work for Hyster-Yale on its latest figures: it has no positive EBITDA to borrow against (−$47.4M over the last 12 months, on revenue of $3.4B). Historically 6.0% of companies with its figures were bought within a year (1.19× the average).
Why a leveraged buyout does not fit
A leveraged buyout is paid for mostly with debt that the company's own cash flow repays. Hyster-Yale's EBITDA over the last 12 months was −$47.4M on revenue of $3.4B, so there is nothing to lend against and nothing to repay a loan with: a buyer would have to pay almost entirely with its own money. That is the kind of deal another company — a strategic buyer that wants the products, the pipeline or the technology — makes, not a private-equity fund. The model therefore gives no buyout price.
What a takeover could cost
Takeovers in its sector paid a median premium of 40% over the share price before the deal (the middle half 14.7% to 60.2%), according to the 20 merger proxies and tender-offer responses on EDGAR that state a premium. At the median, Hyster-Yale would cost about $39.89 a share, $715M for all its shares.
| Premium | % | Price a share | All shares |
|---|---|---|---|
| Low end (a quarter of deals paid less) | 14.7% | $32.68 | $586M |
| Median | 40% | $39.89 | $715M |
| High end (a quarter paid more) | 60.2% | $45.64 | $818M |
The odds, from history
Historically 6.0% of companies with its figures were bought within a year (1.19× the average). Its figures put it in decile 8 of 10 (10 = the most likely to be bought). The odds come from a model of every merger proxy, tender-offer response and going-private statement filed on EDGAR since 2011, set against each company's size, margins, debt, cash flow and growth the year before.
Hyster-Yale's latest quarter
Hyster-Yale, Q3 2026: revenue $827M (-16% year over year), operating margin -1.1%, net loss $14.3M, operating cash flow $26.3M. The chart follows the revenue to costs, profit and cash.
Questions
Is Hyster-Yale being acquired?
No headline, 8-K or 13D about a sale is on file in the last year.
Could private equity buy Hyster-Yale?
A leveraged buyout does not work for Hyster-Yale on its latest figures: it has no positive EBITDA to borrow against (−$47.4M over the last 12 months, on revenue of $3.4B). With no cash flow to repay a loan, a buyer would pay almost entirely with its own money: a deal for another company (a strategic buyer), not for a private-equity fund.
What would a takeover of Hyster-Yale cost?
Takeovers in its sector paid a median premium of 40% over the share price before the deal (the middle half 14.7% to 60.2%), according to the 20 merger proxies and tender-offer responses on EDGAR that state a premium. At the median, Hyster-Yale would cost about $39.89 a share, $715M for all its shares.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.